Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma.
Despite Mexico’s efforts to improve its regulatory framework and create a better business environment for pharma, the market share of generic drugs still makes it difficult for multinationals to materialize their commercial benefit. However, a new report from Business Monitor forecasts that, in the long term, Mexico’s improving private health insurance sector and potentially significant investment from the government will boost patented drug consumption in the country.
Business Monitor’s Mexico Pharmaceuticals & Healthcare Report outlines the following key trends and developments over the last few months:
Business Monitor forecasts real GDP growth in Mexico to accelerate from 1.5% in 2013 to 3.5% in 2014, amid an acceleration in household spending growth and an improvement in investment, bolstered by a successful reform drive in 2013. Exports will also pick up this year as US demand for manufacturing exports strengthens, the report states.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.